In recent years, the pharmaceutical landscape has been undergoing significant shifts, particularly in the domain of oncology therapeutics. Protein-bound paclitaxel, a widely recognized formulation used in the treatment of various solid tumors, has historically enjoyed market exclusivity due to its patented technology and clinical efficacy. However, the surge in biosimilar development is now challenging this exclusivity, reshaping not only market dynamics but also impacting patient access and
...
Read more »